Gregory Maness Allen
Hematology/Oncology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
- Since medical school
- 13 years
- Graduated 2013
Offices
3 locations · UCSF Medical Group Business Services · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Gregory Maness Allen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,169
Medicare paid this office $16,169 for 41 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 39 | $13,902 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 29 | $1,374 | $15 |
Who their Medicare patients are
41 Original Medicare patients in 2024. Average age 73 · Women 37% · Also on Medicaid 37% · Health risk score 2.52. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 75% · Coronary heart disease 32% · COPD 29%.
The office billed $105,776, Medicare allowed $22,111 and paid $16,169; for 222 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 41 | 222 | 73 | 2.52 | $105,776 | $16,169 |
| 2023 | 39 | 413 | 72 | 2.47 | $91,831 | $14,226 |
| 2022 | 40 | 309 | 72 | 2.10 | $115,952 | $17,476 |
| 2021 | 45 | 127 | 72 | 2.91 | $78,558 | $11,751 |
| 2020 | 38 | 146 | 73 | 2.94 | $100,750 | $12,663 |
| 2019 | 42 | 117 | 72 | 2.50 | $96,705 | $11,920 |
| 2018 | 41 | 64 | 71 | 2.38 | $53,287 | $6,966 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 23 | $5,859 | $127 |
| Return visit (30+ min) | 31 | $4,796 | $81 |
2022: 1 service
| Return visit (30+ min) | 37 | $8,066 | $86 |
2021: 4 services
| Return visit (30+ min) | 33 | $7,015 | $86 |
| New patient visit (60+ min) | 12 | $1,996 | $166 |
| Long return visit (40+ min) | 11 | $1,802 | $120 |
| Short return visit (20+ min) | 11 | $668 | $51 |
2020: 3 services
| Long return visit (40+ min) | 22 | $8,227 | $97 |
| Return visit (30+ min) | 15 | $1,997 | $71 |
| New patient visit (60+ min) | 11 | $1,436 | $131 |
2019: 2 services
| Long return visit (40+ min) | 30 | $8,793 | $96 |
| New patient visit (60+ min) | 22 | $2,858 | $130 |
2018: 2 services
| Long return visit (40+ min) | 30 | $4,936 | $99 |
| New patient visit (60+ min) | 13 | $1,937 | $149 |
Drugs they prescribed that Part D paid
$847,238
Pharmacies billed $847,238 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
47 generic and 56 brand-name prescriptions · $847,238 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 36 | $716,117 | $19,892 |
| Ondansetron | 13 | $137 | $11 |
Year by year
| 2024 | 103 | 18 | None | 54% | $847,238 |
| 2023 | 88 | 12 | None | 48% | $444,154 |
| 2022 | 68 | 14 | None | 51% | $283,765 |
| 2021 | 116 | 20 | None | 48% | $583,407 |
| 2020 | 108 | 19 | None | 47% | $586,160 |
| 2019 | 119 | 22 | None | 26% | $454,315 |
| 2018 | 39 | 14 | None | None | $80,699 |
| 2016 | 29 | 13 | None | None | $2,284 |
| 2015 | 238 | 26 | 7% (17) | None | $10,206 |
| 2014 | 309 | 67 | 16% (48) | None | $13,690 |
| 2013 | 63 | 17 | None | None | $3,758 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Tagrisso | 24 | $430,235 | $17,926 |
| Prochlorperazine Maleate | 14 | $204 | $15 |
| Ondansetron | 18 | $194 | $11 |
2022: 2 drugs
| Tagrisso | 17 | $275,635 | $16,214 |
| Eliquis | 12 | $6,770 | $564 |
2021: 2 drugs
| Tagrisso | 36 | $544,895 | $15,136 |
| Ondansetron | 14 | $148 | $11 |
2020: 1 drug
| Tagrisso | 36 | $535,796 | $14,883 |
2019: 5 drugs
| Tagrisso | 27 | $443,002 | $16,407 |
| Dexamethasone | 11 | $408 | $37 |
| Ondansetron | 20 | $247 | $12 |
| Prochlorperazine Maleate | 16 | $167 | $10 |
| Lorazepam | 17 | $91 | $5 |
2015: 6 drugs
| Amlodipine Besylate | 29 | $164 | $6 |
| Atorvastatin | 15 | $135 | $9 |
| Pantoprazole | 13 | $120 | $9 |
| Lisinopril | 26 | $114 | $4 |
| Hydrochlorothiazide | 24 | $50 | $2 |
| Carvedilol | 12 | $43 | $4 |
2014: 6 drugs
| Metoprolol | 22 | $418 | $19 |
| Oxycodone | 14 | $190 | $14 |
| Lisinopril | 37 | $173 | $5 |
| Tramadol | 20 | $172 | $9 |
| Hydrochlorothiazide | 29 | $79 | $3 |
| Metformin | 12 | $71 | $6 |
Money from drug and device companies
$30 in 2021
A payment is not proof that care is biased.
| Pharmacyclics LLC An AbbVie | Imbruvica | $30 | 1 payment
|
See the published payment
| Pharmacyclics LLC An AbbVie | Meals · 2021-04-05 | Imbruvica | $30 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bayer HealthCare Pharmaceuticals Inc. · Bay94-8862, Finerenone Phase 3 in Non-Diabetic Ckd · 2022 | Their institution | $5,300 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1376986331
- Licence
- MD 0276
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 600 N Wolfe St, Baltimore, MD, 21287
- NPI first listed
- 2013-04-09
- NPI last updated
- 2013-04-24
This is when the NPI record was last certified, not a medical board exam.